We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q4 Earnings
Read MoreHide Full Article
In its upcoming report, Johnson & Johnson (JNJ - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.27 per share, reflecting a decline of 3.4% compared to the same period last year. Revenues are forecasted to be $21.1 billion, representing a year-over-year decrease of 11%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Johnson & Johnson metrics that Wall Street analysts commonly model and monitor.
According to the collective judgment of analysts, 'Sales- MedTech - Total' should come in at $7.48 billion. The estimate indicates a year-over-year change of +10.4%.
Based on the collective assessment of analysts, 'Sales- Innovative Medicine - Total' should arrive at $13.41 billion. The estimate indicates a change of +1.9% from the prior-year quarter.
The average prediction of analysts places 'Sales- MedTech- Orthopaedics - Trauma' at $730.37 million. The estimate indicates a year-over-year change of +2.9%.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Orthopaedics - Spine, Sports & Other' of $713.93 million. The estimate indicates a year-over-year change of +2.1%.
Analysts predict that the 'Sales- MedTech- Orthopaedics - Hips - US' will reach $262.75 million. The estimate indicates a change of +5.1% from the prior-year quarter.
The combined assessment of analysts suggests that 'Sales- MedTech- Orthopaedics - Hips - International' will likely reach $137.28 million. The estimate suggests a change of +1.7% year over year.
Analysts expect 'Sales- MedTech- Orthopaedics - Knees - US' to come in at $235.76 million. The estimate indicates a change of +2.1% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Orthopaedics - Knees - International' stands at $131.17 million. The estimate indicates a change of +7.5% from the prior-year quarter.
It is projected by analysts that the 'Sales- MedTech- Orthopaedics - Trauma - US- Trauma' will reach $481.53 million. The estimate indicates a year-over-year change of +2.5%.
The consensus among analysts is that 'Sales- MedTech- Orthopaedics - Trauma - International' will reach $246.18 million. The estimate points to a change of +2.6% from the year-ago quarter.
Analysts forecast 'Sales- MedTech- Orthopaedics - Spine, Sports & Other - US' to reach $442.04 million. The estimate indicates a change of +1.9% from the prior-year quarter.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics - Spine, Sports & Other - International' reaching $270.63 million. The estimate indicates a year-over-year change of +2.1%.
Over the past month, shares of Johnson & Johnson have returned +4.7% versus the Zacks S&P 500 composite's +0.6% change. Currently, JNJ carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q4 Earnings
In its upcoming report, Johnson & Johnson (JNJ - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.27 per share, reflecting a decline of 3.4% compared to the same period last year. Revenues are forecasted to be $21.1 billion, representing a year-over-year decrease of 11%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Johnson & Johnson metrics that Wall Street analysts commonly model and monitor.
According to the collective judgment of analysts, 'Sales- MedTech - Total' should come in at $7.48 billion. The estimate indicates a year-over-year change of +10.4%.
Based on the collective assessment of analysts, 'Sales- Innovative Medicine - Total' should arrive at $13.41 billion. The estimate indicates a change of +1.9% from the prior-year quarter.
The average prediction of analysts places 'Sales- MedTech- Orthopaedics - Trauma' at $730.37 million. The estimate indicates a year-over-year change of +2.9%.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Orthopaedics - Spine, Sports & Other' of $713.93 million. The estimate indicates a year-over-year change of +2.1%.
Analysts predict that the 'Sales- MedTech- Orthopaedics - Hips - US' will reach $262.75 million. The estimate indicates a change of +5.1% from the prior-year quarter.
The combined assessment of analysts suggests that 'Sales- MedTech- Orthopaedics - Hips - International' will likely reach $137.28 million. The estimate suggests a change of +1.7% year over year.
Analysts expect 'Sales- MedTech- Orthopaedics - Knees - US' to come in at $235.76 million. The estimate indicates a change of +2.1% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Orthopaedics - Knees - International' stands at $131.17 million. The estimate indicates a change of +7.5% from the prior-year quarter.
It is projected by analysts that the 'Sales- MedTech- Orthopaedics - Trauma - US- Trauma' will reach $481.53 million. The estimate indicates a year-over-year change of +2.5%.
The consensus among analysts is that 'Sales- MedTech- Orthopaedics - Trauma - International' will reach $246.18 million. The estimate points to a change of +2.6% from the year-ago quarter.
Analysts forecast 'Sales- MedTech- Orthopaedics - Spine, Sports & Other - US' to reach $442.04 million. The estimate indicates a change of +1.9% from the prior-year quarter.
Analysts' assessment points toward 'Sales- MedTech- Orthopaedics - Spine, Sports & Other - International' reaching $270.63 million. The estimate indicates a year-over-year change of +2.1%.
View all Key Company Metrics for Johnson & Johnson here>>>
Over the past month, shares of Johnson & Johnson have returned +4.7% versus the Zacks S&P 500 composite's +0.6% change. Currently, JNJ carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>